This is a study to understand efficacy and safety of investigational agent (PF-04937319) compared to approved agent (glimepiride) in patients with diabetes on metformin
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
304
Combination of tablets and capsules, a total of 3 pills/dose, administered once daily for 84-days
Combination of tablets and capsules, dose of 10 mg, a total of 3 pills/dose, administered once daily for 84-days
Combination of tablets and capsules, dose of 50 mg, a total of 3 pills/dose, administered once daily for 84-days
Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 12
HbA1c is a form of hemoglobin which is measured primarily to identify the average glycemic control over prolonged periods of time. The normal range for the HbA1c test, was identified as less than 6.5 percent by the study-specific central laboratory used. Change from baseline in percentage of HbA1C was reported.
Time frame: Baseline (Day 1), Week 12
Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 2, 4, 6 and 8
HbA1c is a form of hemoglobin which is measured primarily to identify the average glycemic control over prolonged periods of time. The normal range for the HbA1c test, was identified as less than 6.5 percent by the study-specific central laboratory used. Change from baseline in percentage of HbA1C was reported.
Time frame: Baseline (Day 1), Week 2, 4, 6, 8
Change From Baseline in Fasting Plasma Glucose at Week 2, 4, 6, 8 and 12
Time frame: Baseline (Day 1), Week 2, 4, 6, 8, 12
Percentage of Participants Achieving Less Than 6.5 Percent and Less Than 7 Percent Glycosylated Hemoglobin (HbA1c) Levels at Week 12
HbA1c is a form of hemoglobin which is measured primarily to identify the average glycemic control over prolonged periods of time. The normal range for the HbA1c test, was identified as less than 6.5 percent by the study-specific central laboratory used and data are presented in categories of less than 6.5 percent and less than 7 percent.
Time frame: Week 12
Number of Participants With Increase From Baseline Electrocardiogram (ECG) Data
Participants who met the criteria for increase from baseline in ECG data were reported. Criteria for increase from baseline data: PR interval (percent change of greater than or equal to \[\>=\] 25/50% \[if baseline value was \>200 then percent change of \>25% counts; if baseline value was \<=200 then percent change of \>50% counts\]); QRS complex (percent change of \>=50%); QT Fridericia's correction (QTcF) interval (change of \>= 30 to \<60 millisecond \[msec\], and change of \>=60 msec).
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Combination of tablets and capsules, dose of 100 mg, a total of 3 pills/dose, administered once daily for 84-days
Combination of tablets and capsules, dose of up to 6 mg, a total of 3 pills/dose, administered once daily for 84-days
Sierra Clinical Research
Roseville, California, United States
California Research Foundation
San Diego, California, United States
Diablo Clinical Research, Inc.
Walnut Creek, California, United States
Meridien Research
Bradenton, Florida, United States
South Broward Research, LLC
Pembroke Pines, Florida, United States
East-West Medical Research Institute
Honolulu, Hawaii, United States
Clinical Research Center of Cape Cod, Inc.
Hyannis, Massachusetts, United States
Diabetes & Endocrinology Consultants, PC
Morehead City, North Carolina, United States
Sterling Research Group, Ltd.
Cincinnati, Ohio, United States
Community Research
Cincinnati, Ohio, United States
...and 43 more locations
Time frame: Baseline (Day 1) up to Week 14
Number of Participants With Increase/Decrease From Baseline Vital Signs Data
Participants who met the criteria for increase or decrease in vital signs data were reported. Criteria for increase or decrease from baseline vital signs data: sitting systolic blood pressure (BP) of \>=30 millimeter of mercury (mmHg); sitting diastolic BP of \>=20 mmHg and pulse rate was based on investigator's discretion.
Time frame: Baseline (Day 1) up to Week 14
Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 14 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious adverse events.
Time frame: Baseline (Day 1) up to 14 days after last dose of study treatment (up to 101 days)
Percentage of Participants With at Least 1 Hypoglycemic Events (HAE) Episode
A hypoglycemic event was identified by characteristic symptoms or blood glucose levels. HAE was defined as 1 of the given definitions: Characteristic symptoms of HAE with no home glucose monitoring performed where clinical picture included prompt resolution with food intake, subcutaneous glucagon, or intravenous glucose; or characteristic symptoms of HAE with home glucose monitoring measurement =\< 70 milligram per deciliter (mg/dL) using ACCU-CHEK plasma-referenced home glucometers or =\<74 mg/dL using International Federation of Clinical Chemistry (IFCC) referenced ACCU-CHEK or central laboratory glucometers; or any laboratory glucose value, meeting the following criterion with or without accompanying symptoms: =\<49 mg/dL using ACCU-CHEK plasma-referenced home glucometers or =\<53 mg/dL using IFCC referenced ACCU-CHEK or central laboratory glucometers.
Time frame: Baseline (Day 1) up to Week 14
Number of Hypoglycemic Events (HAE) Episodes Per Participant
A hypoglycemic event was identified by characteristic symptoms or blood glucose levels. Median of 1 and 2 events per participant was reported.
Time frame: Baseline (Day 1) up to Week 14
Time to Each Recurrent Hypoglycemic Events (HAE) Episode Per Participant
Median recurrence time was not to be calculated when less than 50% of the participants in a given arm experienced 1 or more HAEs.
Time frame: Baseline (Day 1) up to Week 14
Change From Baseline in Body Weight at Week 2, 4, 6, 8, 12 and 14
Time frame: Baseline (Day 1), Week 2, 4, 6, 8, 12, 14 (follow-up)
Number of Participants With Abnormal Laboratory Values
Hemoglobin,hematocrit,red blood cells(RBC) count:less than \[\<\]0.8\*lower limit of normal \[LLN\],platelets:\<0.5\*LLN/greater than \[\>\]1.75\*upper limit of normal \[ULN\],white blood cells(WBC):\<0.6\*LLN or \>1.5\*ULN,lymphocytes,total neutrophils:\<0.8\*LLN or \>1.2\*ULN, basophils,eosinophil,monocytes:\>1.2\*ULN;aspartate aminotransferase,alanine aminotransferase, alkaline phosphatase:\>0.3\*ULN,total protein,albumin:\<0.8\*LLN or \>1.2\*ULN;total bilirubin,direct bilirubin,indirect bilirubin:\>1.5\*ULN;triglycerides,cholesterol:\>1.3\*ULN, HDL:\<0.8\*LLN, LDL:\>1.2\*ULN,blood urea nitrogen,creatinine:\>1.3\*ULN,uric acid:\>1.2\*ULN;sodium: \<0.95\*LLN or \>1.05\*ULN,potassium,chloride,calcium,bicarbonate:\<0.9\*LLN or \>1.1\*ULN;creatine kinase:\>2.0\*ULN;glucose:\<0.6\*LLN or \>1.5\*ULN,urine WBC and RBC:\>= 20/High Power Field \[HPF\]),urine epithelial cells (\>=1 HPF),urine bacteria \>20 high-powered field;qualitative urine glucose,urine blood to Hgb ratio (\>=1);urine(protein,nitrite,mucus,leukocyte \>=1 in urine dipstick test).
Time frame: Baseline (Day 1) up to Week 14